STAT+: Takeda autoimmune therapy shows effectiveness in key trial
STAT
MARCH 18, 2023
Doctors and investors are getting their first glimpse of the data that compelled Takeda Pharmaceutical to make a $6 billion bet on an experimental pill. The drug, which it acquired from Boston biotech Nimbus Therapeutics last month, blocks a key lever in the immune system that Takeda believes has the potential to treat numerous autoimmune and inflammatory diseases.
Let's personalize your content